ACC 2024 | IVUS-DCB

Drug-coated balloons (DCB) have proven to be effective in the treatment of femoropopliteal pathology, although they entail complications such as recoil, residual stenosis, and dissection.

ACC 2024

Their outcomes could be improved through proper and enhanced vessel preparation, both before and after the procedure. Intravascular ultrasound (IVUS) offers the advantage of characterizing plaque and assessing vessel diameter.

The aim of this study was to compare IVUS-guided angioplasty vs. conventional angiography in DCB (IN.PACT, Medtronic) treatment of femoropopliteal disease. Researchers included a total of 237 patients from 7 centers in Korea; these subjects were randomized to IVUS (n=119) and angiography (n=118). The primary endpoint was primary patency (PP) at 12 months.

The average age was 69 years; 85.7% of patients were men, 74.8% had claudication, and the rest had critical limb ischemia. Regarding characteristics, most lesions were TASC II C/D (67.2%).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

Technical success was achieved in 76.5% of IVUS patients and 61% of those undergoing angiography. Post-procedure ankle-brachial index (ABI) was 0.99 and 0.93, respectively. When evaluating PP, better outcomes were observed in the IVUS arm (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.25-0.85; Log-rank P= 0.01). Additionally, considering secondary events, IVUS-guided treatment showed better results in terms of revascularization-free vessel (HR, 0.41; 95% CI, 0.19-0.90; Log-rank P= 0.03) and sustained clinical improvement (HR, 0.45; 95% CI, 0.23-0.86; Log-rank P=0.02).

In conclusion, IVUS guidance significantly improved DCB treatment outcomes in femoropopliteal disease, with better primary patency, greater freedom from new revascularization, and clinical improvement at 12 months.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparación de angioplastia dirigida por IVUS vs dirigido por angiografía en el tratamiento con balón con drogas para territorio femoropoplíteo. 

Reference: Presentado por Dr. Young-Guk Ko en ACC.24 Late-Breaking Clinical Trials, 6-8 de abril, Atlanta.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....